Z 100

Drug Profile

Z 100

Alternative Names: Ancer-20; SSM; Z-100

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zeria
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Lipids; Mannans
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leucopenia
  • Phase III Cervical cancer
  • Discontinued HIV infections; Rheumatoid arthritis

Most Recent Events

  • 23 Mar 2018 Zeria Pharmaceutical plans a phase III study for Cervical Cancer (Late-stage disease) in Vietnam (NCT03476018)
  • 17 Jan 2018 Z 100 is still in phase III trials for Cervical cancer (First-line therapy, Late-stage disease) in Japan, South Korea, Malaysia, Singapore, Taiwan, Thailand and Vietnam (NCT02247232)
  • 08 May 2015 Z 100 is still in phase III trials for Cervical cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top